JUL 22·SEC EDGARLow
Chernett Jorey purchased $95K of DFPH
Chernett Jorey purchased 18,000 shares of Oncology Institute, Inc. (DFPH) at $5.27 on 2026-07-21.
StockNASDAQ · US · USDHealthcare · Medical Care Facilities
$TOI
Oncology Institute, Inc.
Price · $TOIvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $TOI in the last 7 days.
Top stories · $TOIMore →
JUL 16·leaderpost.com
Topicus.com Inc. Announces Release Date for Second Quarter Results
Topicus.com Inc. (TSXV:TOI) said it will release its second-quarter results on Aug. 5, 2026, after markets close. The company plans to publish the results via press release and post them on its website and on SEDARPlus. The announcement relates to its upcoming quarterly earnings.
JUL 15·finanznachrichten.de
Biotech Stocks Hit 52-Week Highs - TOI, IKT, ANRO, ELV, PRVA
Biotech and healthcare stocks hit 52-week highs on July 14, 2026. The Oncology Institute (TOI) reached $6.66 after repaying an $86 million senior convertible note and projecting 2026 revenue of $630 million to $650 million. Inhibikase (IKT) rose above $2.36 after a $50 million ATM sale. Alto Neuroscience (ANRO) hit $28.85 after a $100 million direct offering. Elevance (ELV) touched $434.38, guiding 2026 adjusted diluted EPS of at least $26.75. Privia (PRVA) hit $28.30, estimating 2026 GAAP reven
TOI sentiment & insider activity
Recent TOI coverage spans insider activity, financial news and corporate actions.
In the last 30 days, TOI insiders filed 4 SEC Form 4 transactions — 2 purchases ($183K) and 2 sales ($150K). The most active reporter was Chernett Jorey with 2 filings. 50% of activity was filed under pre-arranged Rule 10b5-1 plans.
What's driving TOI
Chernett Jorey purchased 18,000 shares of Oncology Institute, Inc. (DFPH) at $5.27 on 2026-07-21.
The article is a scheduling update for the next earnings release, which can drive positioning and volatility into Aug. 5.
Capital structure de-risking plus fresh credit facilities can support near-term funding confidence, consistent with the 52-week high move.
This is a routine insider open-market purchase with no 10b5-1 plan, but it does not disclose new fundamentals or guidance.
Refinancing without equity dilution should reduce balance-sheet overhang and support a valuation re-rate, with near-term focus on 2Q26 revenue and EBITDA seasonality.
alphai scores every news story that mentions TOI with an AI model for sentiment and relevance, and aggregates insider trades from Oncology Institute, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $TOI
Score
Chernett Jorey purchased $95K of DFPH
Chernett Jorey purchased 18,000 shares of Oncology Institute, Inc. (DFPH) at $5.27 on 2026-07-21.
1 min readTopicus.com Inc. Announces Release Date for Second Quarter Results
Topicus.com Inc. (TSXV:TOI) said it will release its second-quarter results on Aug. 5, 2026, after markets close. The company plans to publish the results via press release and post them on its website and on SEDARPlus. The announcement relates to its upcoming quarterly earnings.
1 min readBiotech Stocks Hit 52-Week Highs - TOI, IKT, ANRO, ELV, PRVA
Biotech and healthcare stocks hit 52-week highs on July 14, 2026. The Oncology Institute (TOI) reached $6.66 after repaying an $86 million senior convertible note and projecting 2026 revenue of $630 million to $650 million. Inhibikase (IKT) rose above $2.36 after a $50 million ATM sale. Alto Neuroscience (ANRO) hit $28.85 after a $100 million direct offering. Elevance (ELV) touched $434.38, guiding 2026 adjusted diluted EPS of at least $26.75. Privia (PRVA) hit $28.30, estimating 2026 GAAP reven
4 min readChernett Jorey purchased $88K of TOI
Chernett Jorey purchased 15,000 shares of Oncology Institute, Inc. (TOI) at $5.85 on 2026-07-10.
2 min readThis Stock Just Topped B Riley’s Conference Best Ideas List By Investing.com
B. Riley Securities named The Oncology Institute (TOI) its Best Idea from a May conference and reiterated a buy rating with an $8 price target. TOI refinanced $86M convertible debt due Aug 2027 using a $75M OrbiMed term loan and $11M cash, avoiding equity. B. Riley cites improved free cash flow and projects Q2 2026 revenue of $152.8M.
4 min readOncology Institute, Inc. (TOI): Entry into a Material Definitive Agreement
Oncology Institute, Inc. (TOI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10x1.htm CREDIT AGREEMENT Exhibit 10.1 CREDIT AGREEMENT dated as of July 1, 2026 by and among THE ONCOLOGY INSTITUTE, INC., as the Borrower, ORBIMED OPPORTUNITIES (CA) V LLC, as the Initial Lender, and ORBIMED OPPORTUNITIES (CA) V LLC, as the Administrative Agent TABL
3 min readChernett Jorey purchased $90K of TOI
Chernett Jorey purchased 18,000 shares of Oncology Institute, Inc. (TOI) at $5.02 on 2026-06-23.
2 min readOncology Institute, Inc. (TOI): Submission of Matters to a Vote of Security Holders
Oncology Institute, Inc. (TOI) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Current Report false 0001799191 0001799191 2026-06-17 2026-06-17 0001799191 TOI:CommonStockParValue0.0001Member 2026-06-17 2026-06-17 0001799191 TOI:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockEachAtExercisePriceOf11.50PerShareMember 2026-06-17 2026-06-17
3 min readChernett Jorey purchased $57K of TOI
Chernett Jorey purchased 12,000 shares of Oncology Institute, Inc. (TOI) at $4.75 on 2026-06-04.
2 min read
Canadian Stocks to Buy Today and Hold for the Next 7 Years
The article highlights three Canadian stocks for a 7-year hold: Canadian National Railway (CNR), Alimentation Couche-Tard (ATD), and Topicus.com (TOI). CNR reported Q1 revenue of $4.4B and free cash flow of $900M (+44% YoY) and repurchased $869M of shares. ATD’s fiscal Q3 adjusted EPS rose 19.1% to US$0.81; merchandise and service revenue grew 8.7% to US$5.8B. Topicus reported Q1 2026 revenue up 23% to €435.7M and free cash flow to shareholders up 2% to €165.4M.
6 min read